FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327884269> ?p ?o ?g. }

• W4327884269 abstract "Background: Today, various drugs have been investigated as the primary or complementary treatment for coronavirus disease 2019 (COVID-19). N-acetylcysteine (NAC) has been used as a mucolytic in pulmonary diseases. This drug apparently contributes to the retrieval of the intracellular antioxidant system. Objectives: This study aimed to determine the efficacy of NAC in severe COVID-19 patients admitted to the intensive care unit (ICU). Methods: This single-blinded randomized controlled phase III clinical trial included 40 patients with confirmed COVID-19 (based on polymerase chain reaction) admitted to the Shahid Mohammadi Hospital’s ICU, Bandar Abbas, Iran, in 2020. All cases had severe COVID-19. They were allocated randomly to two equal groups. Patients in the control group received standard drug therapy based on the treatment protocol of the national COVID-19 committee, while those in the NAC group received a single dose of intravenous NAC (300 mg/kg) upon admission to the ICU in addition to standard drug treatment. Clinical status and laboratory tests were done on admission to the ICU and then 14 days later or at discharge without knowing the patient grouping. Results: The two groups were comparable regarding age, gender, and other baseline laboratory and clinical parameters. At the final evaluation, respiratory rate (21.25 ± 4.67 vs. 27.37 ± 6.99 /min) and D-dimer (186.37 ± 410.23 vs. 1339.04 ± 2183.87 ng/mL) were significantly lower in the NAC group (P = 0.004 and P = 0.030, respectively). Also, a lower percentage of patients in the NAC group had lactate dehydrogenase (LDH) ≤ 245 U/L (0% vs. 25%, P = 0.047). Although the length of ward and ICU stay was shorter in the NAC group than in controls, the difference was statistically insignificant (P = 0.598 and P = 0.629, respectively). Mortality, on the other hand, was 75% in the control group and 50% in the NAC group, with no statistically significant difference (P = 0.102). Concerning the change in the study parameters, only the decrease in diastolic blood pressure (DBP) was significantly higher with NAC (P = 0.042). The intubation and mechanical ventilation rates were higher, while oxygen with mask and nasal oxygen rates were lower with NAC, but the difference was statistically insignificant. Conclusions: Based on the current research, NAC is related to a significant decrease in RR, D-dimer, and DBP in severe COVID-19. Also, LDH was significantly lower in the NAC group than in the controls. More research with larger sample sizes is needed to validate the current study results." @default.
• W4327884269 created "2023-03-21" @default.
• W4327884269 creator A5009422520 @default.
• W4327884269 creator A5010292235 @default.
• W4327884269 creator A5015328744 @default.
• W4327884269 creator A5025390069 @default.
• W4327884269 creator A5030673084 @default.
• W4327884269 creator A5038683308 @default.
• W4327884269 creator A5040430384 @default.
• W4327884269 creator A5054968591 @default.
• W4327884269 creator A5081347544 @default.
• W4327884269 creator A5083566186 @default.
• W4327884269 date "2023-01-13" @default.
• W4327884269 modified "2023-10-01" @default.
• W4327884269 title "Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial" @default.
• W4327884269 cites W1705729852 @default.
• W4327884269 cites W2085076776 @default.
• W4327884269 cites W2157305642 @default.
• W4327884269 cites W2519786994 @default.
• W4327884269 cites W2810242058 @default.
• W4327884269 cites W2889620461 @default.
• W4327884269 cites W2910161726 @default.
• W4327884269 cites W2913407408 @default.
• W4327884269 cites W2947816026 @default.
• W4327884269 cites W3009912996 @default.
• W4327884269 cites W3014294089 @default.
• W4327884269 cites W3015184693 @default.
• W4327884269 cites W3016535995 @default.
• W4327884269 cites W3018517500 @default.
• W4327884269 cites W3025141218 @default.
• W4327884269 cites W3026764413 @default.
• W4327884269 cites W3033669631 @default.
• W4327884269 cites W3034022005 @default.
• W4327884269 cites W3039473805 @default.
• W4327884269 cites W3042618958 @default.
• W4327884269 cites W3044394179 @default.
• W4327884269 cites W3087690274 @default.
• W4327884269 cites W3089151044 @default.
• W4327884269 cites W3111724275 @default.
• W4327884269 cites W3116418056 @default.
• W4327884269 cites W3155419305 @default.
• W4327884269 cites W3170317410 @default.
• W4327884269 cites W3176881890 @default.
• W4327884269 cites W3210414471 @default.
• W4327884269 doi "https://doi.org/10.5812/jjnpp-129817" @default.
• W4327884269 hasPublicationYear "2023" @default.
• W4327884269 type Work @default.
• W4327884269 citedByCount "0" @default.
• W4327884269 crossrefType "journal-article" @default.
• W4327884269 hasAuthorship W4327884269A5009422520 @default.
• W4327884269 hasAuthorship W4327884269A5010292235 @default.
• W4327884269 hasAuthorship W4327884269A5015328744 @default.
• W4327884269 hasAuthorship W4327884269A5025390069 @default.
• W4327884269 hasAuthorship W4327884269A5030673084 @default.
• W4327884269 hasAuthorship W4327884269A5038683308 @default.
• W4327884269 hasAuthorship W4327884269A5040430384 @default.
• W4327884269 hasAuthorship W4327884269A5054968591 @default.
• W4327884269 hasAuthorship W4327884269A5081347544 @default.
• W4327884269 hasAuthorship W4327884269A5083566186 @default.
• W4327884269 hasBestOaLocation W43278842691 @default.
• W4327884269 hasConcept C126322002 @default.
• W4327884269 hasConcept C138885662 @default.
• W4327884269 hasConcept C168563851 @default.
• W4327884269 hasConcept C185592680 @default.
• W4327884269 hasConcept C27206212 @default.
• W4327884269 hasConcept C2776376669 @default.
• W4327884269 hasConcept C2777847592 @default.
• W4327884269 hasConcept C2778004101 @default.
• W4327884269 hasConcept C2778796999 @default.
• W4327884269 hasConcept C2779134260 @default.
• W4327884269 hasConcept C3008058167 @default.
• W4327884269 hasConcept C524204448 @default.
• W4327884269 hasConcept C535046627 @default.
• W4327884269 hasConcept C55493867 @default.
• W4327884269 hasConcept C71924100 @default.
• W4327884269 hasConceptScore W4327884269C126322002 @default.
• W4327884269 hasConceptScore W4327884269C138885662 @default.
• W4327884269 hasConceptScore W4327884269C168563851 @default.
• W4327884269 hasConceptScore W4327884269C185592680 @default.
• W4327884269 hasConceptScore W4327884269C27206212 @default.
• W4327884269 hasConceptScore W4327884269C2776376669 @default.
• W4327884269 hasConceptScore W4327884269C2777847592 @default.
• W4327884269 hasConceptScore W4327884269C2778004101 @default.
• W4327884269 hasConceptScore W4327884269C2778796999 @default.
• W4327884269 hasConceptScore W4327884269C2779134260 @default.
• W4327884269 hasConceptScore W4327884269C3008058167 @default.
• W4327884269 hasConceptScore W4327884269C524204448 @default.
• W4327884269 hasConceptScore W4327884269C535046627 @default.
• W4327884269 hasConceptScore W4327884269C55493867 @default.
• W4327884269 hasConceptScore W4327884269C71924100 @default.
• W4327884269 hasIssue "1" @default.
• W4327884269 hasLocation W43278842691 @default.
• W4327884269 hasOpenAccess W4327884269 @default.
• W4327884269 hasPrimaryLocation W43278842691 @default.
• W4327884269 hasRelatedWork W2017587608 @default.
• W4327884269 hasRelatedWork W2118525882 @default.
• W4327884269 hasRelatedWork W3108634178 @default.
• W4327884269 hasRelatedWork W3132916626 @default.
• W4327884269 hasRelatedWork W3159250744 @default.
• W4327884269 hasRelatedWork W4243931985 @default.

• next